Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTO3 with Pembrolizumab in Relapsed/Refractory DLBCL
NCT03287817Phase 2Terminated
- Sponsor
- Autolus Therapeutics plc
- Start
- Sep 2017
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of AUTO3 in diffuse large B-cell lymphoma (DLBCL), sponsored by Autolus Therapeutics plc. Started Sep 2017; status: terminated.
02
Drugs
AUTO3
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03287817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287817.